In cancer, mutations in RAS result in the persistent activation of RAS proteins, leading to continuous stimulation of the RAS/RAF/MEK/ERK pathway, which drives uncontrolled cell proliferation and tumor development [84]. Here, MAP2K7 is linked to neoplasm.